GWM
AMPH icon

Gilpin Wealth Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Gilpin Wealth Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$104 Sell
4
-4
-50% -$86 ﹤0.01% 1291
2026
Q2 		$162 Buy
8
+3
+60% +$61 ﹤0.01% 958
2026
Q1 		$98 Buy
5
+3
+150% +$73 ﹤0.01% 952
2025
Q4 		$54 Buy
+2
New +$52 ﹤0.01% 941

Other funds holding AMPH

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's AMPH Position: Q3 2026 in Review

Gilpin Wealth Management reduced its Amphastar Pharmaceuticals (AMPH) stake by 50% in Q3 2026, selling an estimated $86 and leaving 4 shares worth $104. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Gilpin Wealth Management first reported a position in AMPH in Q4 2025 and has held it in 4 quarters since. The position peaked at $162 in Q2 2026. 9 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

  • Gilpin Wealth Management held 4 shares of Amphastar Pharmaceuticals worth $104 as of Q3 2026.
  • Gilpin Wealth Management sold 4 Amphastar Pharmaceuticals shares in Q3 2026, an estimated $86.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1291 holding.
  • Gilpin Wealth Management first reported a position in Amphastar Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Amphastar Pharmaceuticals position peaked at $162 in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.